An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib by Mateo, J, Moreno, V, Gupta, A, Kaye, S, Dean, E, Middleton, M, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, K, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S, Molife, L